Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$39.81 - $88.24 $230,898 - $511,791
-5,800 Closed
0 $0
Q3 2021

Nov 17, 2021

BUY
$52.01 - $71.77 $301,658 - $416,266
5,800 New
5,800 $303,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.1B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Altium Capital Management LP Portfolio

Follow Altium Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Altium Capital Management LP with notifications on news.